Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...
Uloženo v:
Hlavní autoři: | , , , , , , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | angličtina |
Vydáno: |
2015
|
On-line přístup: | https://doi.org/10.1111/cas.12814 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12814 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|